Regenerative Medical Technology (RMTG) Other Non Operating Income (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Other Non Operating Income of $1.1 million for Q1 2026, up 94485.73% year-over-year from N/an in Q1 2025, and up 17.75% quarter-over-quarter from $921028.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Other Non Operating Income (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Other Non Operating Income history runs 9 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 94485.73% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $2.0 million (up 91454.92% YoY), while the FY2025 annual figure was $918688.0, up 36226.15% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $1.1 million, up from $921028.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $1.5 million in Q4 2023, with the low at -$1498.0 in Q1 2024.
- The 5-year median for Other Non Operating Income is $964.0 (2023), against an average of $207409.8.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income sank 226.76% in 2024, then surged 103970.96% in 2025.
- Regenerative Medical Technology's Other Non Operating Income stood at $3016.0 in 2022, then jumped by 49880.37% to $1.5 million in 2023, then plunged by 99.94% to $885.0 in 2024, then soared by 103970.96% to $921028.0 in 2025, then rose by 17.75% to $1.1 million in 2026.
- Business Quant data shows RMTG's Other Non Operating Income at $1.1 million in Q1 2026, $921028.0 in Q4 2025, and -$865.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 921,028.00 |
| Sep 30, 2025 | -865.00 |
| Jun 30, 2025 | -328.00 |
| Mar 31, 2025 | -1,149.00 |
| Dec 31, 2024 | 885.00 |
| Sep 30, 2024 | -1,222.00 |
| Jun 30, 2024 | -708.00 |
| Mar 31, 2024 | -1,498.00 |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 964.00 |
| Jun 30, 2023 | 998.00 |
| Mar 31, 2023 | 2,463.00 |
| Dec 31, 2022 | 3,016.00 |
| Sep 30, 2022 | 876.00 |
| Jun 30, 2022 | 3,527.00 |
| Mar 31, 2022 | 6,079.00 |
| Dec 31, 2021 | -2.49 Mn |
| Jun 30, 2021 | -231,109.00 |
| Dec 31, 2020 | 8.60 Mn |